Vertex Pharmaceuticals jolted Wall Street with a fresh batch of midstage data on one of its combo therapies against cystic fibrosis.
Researchers at Cornell University have created the prototype of a combination drug-delivery and diagnostic nanoparticle that would be the smallest inorganic, silica-based vehicle around.
Steve Eaton, the former Aptuit employee convicted of manipulating data from hundreds of drug safety studies, has been ordered serve three months in jail, the first such sentencing under the U.K.'s tightened research regulations.
United Kingdom-based Immune Targeting Systems (ITS) showed data from a Phase IIa trial of its candidate, Flunisyn, at the World Vaccine Congress this week.
Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.
As Merck works on rebooting R&D, the drug giant has rewarded a pair of its biotech partners in Canada for their progress with separate preclinical programs. This week Xenon and Zymeworks, both headquartered in Vancouver, have reported new developments in their partnerships with Merck.
Tech visionary Peter Thiel, recently named one of FierceBiotech 's top biotech billionaires and an early venture investor in Facebook, has chosen two recipients of the first round of grants of up to $350,000--Stealth Biosciences and Skyphrase, which are both developing innovative technologies that could have uses in the biopharma space.
A new analysis shows that the biggest biotech players have outperformed a group of pharma giants over the previous three years, with the value of the biotech group up 57% compared with 17.4% growth in the pharma camp.
Alkermes has a shot at offering a new option for treating depression in patients who don't respond to existing drugs. The company revealed positive preliminary data from a Phase II study of ALKS 5461, an opioid-receptor targeting drug, which the biotech player now aims to march into pivotal development.
Auris Medical raked in a $50.6 million financing round for its novel drug to treat inner-ear problems via an injection into the middle-ear cavity.